Kaken Pharmaceutical Co., Ltd. (TYO:4521)
Japan · Delayed Price · Currency is JPY 3,825.00
-15.00 (-0.39%)
Nov 13, 2026, 3:30 PM JST
Kaken Pharmaceutical Financials Overview
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Revenue Revenue Growth | 86,472 | 76,871 | 94,035 | 72,044 | 72,984 | 76,034 |
Revenue Growth | 5.43% | -18.25% | 30.52% | -1.29% | -4.01% | 1.41% |
Gross Profit Gross Profit Growth | 49,222 | 39,992 | 58,533 | 38,539 | 39,556 | 41,576 |
Operating Income Operating Income Growth | 9,063 | -899 | 21,036 | 9,514 | 8,000 | 17,065 |
Net Income Net Income Growth | 9,152 | 2,144 | 13,945 | 8,025 | 5,440 | 9,549 |
Earnings Per Share EPS Growth | 241.68 | 56.55 | 365.42 | 212.66 | 144.79 | 251.44 |
EPS Growth | 1318.29% | -84.52% | 71.83% | 46.87% | -42.41% | -27.62% |
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Pharmaceutical Industry Pharmaceutical Industry Growth | 83,886 | 74,328 | 91,553 | 69,613 | 70,562 | 73,623 |
Real Estate Real Estate Growth | 2,586 | 2,543 | 2,481 | 2,430 | 2,422 | 2,410 |
Total Total Growth | 86,472 | 76,871 | 94,034 | 72,043 | 72,984 | 76,033 |
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Investments Cash & Investments Growth | 59,514 | 50,705 | 70,085 | 65,324 | 74,260 | 74,624 |
Total Debt Total Debt Growth | 3,850 | 3,850 | 3,850 | 3,850 | 3,850 | 3,850 |
Net Cash (Debt) Net Cash Growth | 55,664 | 46,855 | 66,235 | 61,474 | 70,410 | 70,774 |
Net Cash Growth | 4.52% | -29.26% | 7.75% | -12.69% | -0.51% | -3.65% |
Net Cash Per Share Net Cash Per Share Growth | 1469.95 | 1235.92 | 1735.63 | 1629.01 | 1874.05 | 1863.55 |
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 11,177 | -11,079 | 29,780 | 2,577 | 9,253 | 13,336 |
Capital Expenditures CapEx Growth | -3,643 | -2,996 | -4,138 | -1,861 | -1,987 | -2,986 |
Free Cash Flow Free Cash Flow Growth | 7,534 | -14,075 | 25,642 | 716 | 7,266 | 10,350 |
Free Cash Flow Growth | - | - | 3481.28% | -90.15% | -29.80% | -16.58% |
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Gross Margin | 56.92% | 52.02% | 62.25% | 53.49% | 54.20% | 54.68% |
Operating Margin | 10.48% | -1.17% | 22.37% | 13.21% | 10.96% | 22.44% |
Pretax Margin | 13.38% | 3.01% | 20.67% | 13.60% | 9.34% | 18.26% |
Profit Margin | 10.58% | 2.79% | 14.83% | 11.14% | 7.45% | 12.56% |
FCF Margin | 8.71% | -18.31% | 27.27% | 0.99% | 9.96% | 13.61% |
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 15, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Dividend Per Share Dividend Per Share Growth | 190.000 | 190.000 | 150.000 | 150.000 | 150.000 | 150.000 |
Dividend Per Share Growth | 0% | 26.67% | 0% | 0% | 0% | 0% |
Dividend Yield | 4.97% | 4.59% | 3.26% | 4.34% | 4.06% | 3.86% |
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 15, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 15.83 | 73.12 | 12.68 | 16.32 | 25.45 | 15.41 |
Forward PE | 24.21 | 77.77 | 22.01 | 19.39 | 13.57 | 13.10 |
P/FCF Ratio | 19.23 | - | 6.90 | 182.95 | 19.06 | 14.21 |
PS Ratio | 1.68 | 2.04 | 1.88 | 1.82 | 1.90 | 1.94 |